Inhibikase Therapeutics (NYSE:IKT) Shares Down 0.3%

Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) fell 0.3% during mid-day trading on Friday . The stock traded as low as $1.54 and last traded at $1.60. 10,251 shares changed hands during trading, a decline of 89% from the average session volume of 89,473 shares. The stock had previously closed at $1.60.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price objective on Inhibikase Therapeutics from $27.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, May 21st.

Inhibikase Therapeutics Price Performance

The firm has a 50-day simple moving average of $1.54 and a two-hundred day simple moving average of $1.91. The company has a market cap of $11.52 million, a PE ratio of -0.48 and a beta of 1.32.

Inhibikase Therapeutics (NYSE:IKT) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. Equities research analysts forecast that Inhibikase Therapeutics, Inc. will post -1.87 EPS for the current year.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.